Decreased levels of urinary liver-type fatty acid-binding protein after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study
Restricted accessResearch articleFirst published online November, 2019
Decreased levels of urinary liver-type fatty acid-binding protein after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study
A single-center, prospective, observational study was conducted between September 2016 and August 2018 in 33 HIV-positive Japanese patients who switched antiretroviral drug regimens from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF). The study assessed changes in urinary levels of liver-type fatty acid-binding protein (L-FABP) after switching from TDF to TAF and determined the potential of renal parameters to predict improvement in estimated glomerular filtration rate (eGFR). Median urinary levels of L-FABP were found to be 2.0, 1.4, and 1.3 µg/g creatinine before, at 6 months, and at 12 months after switching to TAF, respectively. The urinary levels of L-FABP, β2 microglobulin (β2MG), and eGFR and the protein-to-creatinine ratio (PCR) were not significantly related to the annual change in eGFR after switching from TDF to TAF. Our results demonstrate a significant decrease in urinary levels of L-FABP after switching from TDF to TAF. However, neither urinary L-FABP, β2MG, PCR, nor eGFR predicted the annual change in eGFR after the change in medication.
PalellaFJJrBakerRKMoormanAC, et al.
Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr2006;
43: 27–34.
2.
PalellaFJJrDelaneyKMMoormanAC, et al.
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med1998;
338: 853–860.
3.
RolingJSchmidHFischerederM, et al.
HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis2006;
42: 1488–1495.
4.
GoASChertowGMFanD, et al.
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med2004;
351: 1296–1305.
5.
GeorgeELucasGMNadkarniGN, et al.
Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS2010;
24: 387–394.
6.
BanderaAGoriASabbatiniF, et al.
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy. PLoS One2015;
10: e0124252.
7.
AntelaAAguiarCCompstonJ, et al.
The role of tenofovir alafenamide in future HIV management. HIV Med2016;
17: 4–16.
8.
SweetserDAHeuckerothROGordonJI.The metabolic significance of mammalian fatty-acid-binding proteins: abundant proteins in search of a function. Annu Rev Nutr1987;
7: 337–359.
9.
VeerkampJHPeetersRAMaatmanRG.Structural and functional features of different types of cytoplasmic fatty acid-binding proteins. Biochim Biophys Acta1991;
1081: 1–24.
10.
VeerkampJHvan KuppeveltTHMaatmanRG, et al.
Structural and functional aspects of cytosolic fatty acid-binding proteins. Prostaglandins Leukot Essent Fatty Acids1993;
49: 887–906.
11.
KamijoAKimuraKSugayaT, et al.
Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med2004;
143: 23–30.
12.
Kamijo-IkemoriASugayaTYasudaT, et al.
Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care2011;
34: 691–696.
13.
ArakiSHanedaMKoyaD, et al.
Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care2013;
36: 1248–1253.
14.
HikasaSShimabukuroSHidetaK, et al.
Urinary liver-type fatty acid-binding protein levels as a potential risk factor for renal dysfunction in male HIV-infected Japanese patients receiving antiretroviral therapy: a pilot study. Int J STD AIDS2018;
29: 1424–1431.
15.
HikasaSShimabukuroSHidetaK, et al.
Utility of urinary liver-type fatty acid-binding protein as a predictor of renal dysfunction in Japanese patients with HIV receiving tenofovir disoproxil fumarate with low urinary beta2 microglobulin levels: a retrospective observational study. J Pharm Health Care Sci2019;
5: 12.
16.
GallantJEDaarESRaffiF, et al.
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV2016;
3: e158–e165.
17.
PozniakAArribasJRGatheJ, et al.
Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr2016;
71: 530–537.
18.
ArribasJRThompsonMSaxPE, et al.
Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results. J Acquir Immune Defic Syndr2017;
75: 211–218.
19.
PostFATebasPClarkeA, et al.
Brief report: switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr2017;
74: 180–184.
20.
RaffiFOrkinCClarkeA, et al.
Brief report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults. J Acquir Immune Defic Syndr2017;
75: 226–231.
21.
MatsuoSImaiEHorioM, et al.
Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis2009;
53: 982–992.
22.
JablonowskaEWojcikKPiekarskaA.Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir. AIDS Res Hum Retroviruses2014;
30: 363–369.
23.
NishijimaTKomatsuHGatanagaH, et al.
Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One2011;
6: e22661.
24.
PeraltaCScherzerRGrunfeldC, et al.
Urinary biomarkers of kidney injury are associated with all-cause mortality in the women’s interagency HIV Study (WIHS). HIV Med2014;
15: 291–300.
25.
Kamijo-IkemoriASugayaTKimuraK.Urinary fatty acid binding protein in renal disease. Clin Chim Acta2006;
374: 1–7.
26.
Hagins D, Orkin C, Daar ES, et al. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Med 2018; 19: 724--733.
27.
HodderSSquiresKKityoC, et al.
Brief report: efficacy and safety of switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) in virologically suppressed women. J Acquir Immune Defic Syndr2018;
78: 209–213.
28.
MillsACrofootGJrMcDonaldC, et al.
Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr2015;
69: 439–445.
29.
NishijimaTKurosawaTTanakaN, et al.
Urinary beta2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy. AIDS2016;
30: 1563–1571.
30.
PalellaFJJrLiXGuptaSK, et al.
Long-term kidney function, proteinuria, and associated risks among HIV-infected and uninfected men. AIDS2018;
32: 1247–1256.
31.
BanerjeeTScherzerRPoweNR, et al.
Race and other risk factors for incident proteinuria in a national cohort of HIV-infected veterans. J Acquir Immune Defic Syndr2014;
67: 145–152.
32.
CasadoJL.Renal and bone toxicity with the use of tenofovir: understanding at the end. AIDS Rev2016;
18: 59–68.
